Universal Beteiligungs und Servicegesellschaft mbH Has $15.98 Million Position in Incyte Corporation $INCY

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Incyte Corporation (NASDAQ:INCY) by 10.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 188,362 shares of the biopharmaceutical company’s stock after purchasing an additional 17,380 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Incyte were worth $15,975,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Chicago Partners Investment Group LLC boosted its position in Incyte by 49.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 7,888 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 2,619 shares during the period. Forvis Mazars Wealth Advisors LLC raised its stake in shares of Incyte by 1.9% during the third quarter. Forvis Mazars Wealth Advisors LLC now owns 44,207 shares of the biopharmaceutical company’s stock valued at $3,749,000 after acquiring an additional 839 shares during the last quarter. Jackson Thornton Wealth Management LLC lifted its holdings in shares of Incyte by 96.7% during the third quarter. Jackson Thornton Wealth Management LLC now owns 7,124 shares of the biopharmaceutical company’s stock worth $608,000 after purchasing an additional 3,503 shares during the period. Root Financial Partners LLC bought a new stake in shares of Incyte in the third quarter worth $28,000. Finally, QTR Family Wealth LLC acquired a new stake in Incyte in the third quarter valued at $305,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Insider Activity

In related news, EVP Mohamed Khairie Issa sold 10,856 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the transaction, the executive vice president directly owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. This represents a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lee Heeson sold 3,074 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $94.02, for a total value of $289,017.48. Following the completion of the transaction, the executive vice president owned 29,241 shares in the company, valued at approximately $2,749,238.82. The trade was a 9.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 98,897 shares of company stock valued at $9,869,376. Corporate insiders own 17.80% of the company’s stock.

Incyte Trading Down 2.9%

Shares of INCY stock opened at $101.99 on Friday. The company has a market cap of $20.02 billion, a P/E ratio of 17.08, a PEG ratio of 0.63 and a beta of 0.82. Incyte Corporation has a fifty-two week low of $53.56 and a fifty-two week high of $112.29. The stock has a 50 day simple moving average of $101.99 and a two-hundred day simple moving average of $90.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the firm posted $1.07 EPS. The company’s quarterly revenue was up 20.0% on a year-over-year basis. Research analysts forecast that Incyte Corporation will post 4.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on INCY. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $107.00 target price (down from $116.00) on shares of Incyte in a report on Tuesday. Truist Financial set a $103.00 price objective on Incyte in a research note on Wednesday, December 24th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $90.00 target price on shares of Incyte in a report on Thursday, January 8th. Guggenheim upgraded shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price target for the company in a report on Monday, November 3rd. Finally, TD Cowen restated a “buy” rating on shares of Incyte in a research report on Tuesday, January 13th. Eight investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $100.75.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.